“Het zijn écht twee verschillende dingen, benadrukt onderzoeker Jeroen de Ridder van het UMC Utrecht: werken aan de oplossing van een wetenschappelijk probleem en vervolgens die oplossing uitbouwen tot een commercieel product waar patiënten daadwerkelijk iets aan hebben. Voor die tweede stap zijn andere eigenschappen en vaardigheden nodig. Het is dan ook niet vanzelfsprekend dat wetenschappers, die gedurende hun onderzoek nieuwe waardevolle inzichten opdoen, die tweede stap zetten. Ook Jeroen had een duwtje in de rug nodig.” Het UMC Utrecht heeft een lezenswaardig verhaal opgetekend over de ondernemende onderzoeker. Hier lees je meer over de uitdaging die Jeroen aangaat om met zijn start-up Cyclomics een bruikbaar medisch product te ontwikkelen om snel en goedkoop kanker op te sporen met bloedonderzoek.
https://www.hollandbio.nl/wp-content/uploads/2023/08/HollandBIO_logo.svg00HollandBIOhttps://www.hollandbio.nl/wp-content/uploads/2023/08/HollandBIO_logo.svgHollandBIO2020-08-19 09:54:182020-08-19 09:54:19Onderzoekers hebben soms een duwtje in de rug nodig met ondernemen← #nieuws
Deze week hebben wij vanuit HollandBIO onze inbreng geleverd op de zogeheten roadmap voor Intellectual property action plan (actieplan voor intellectueel eigendom) van de Europese Commissie. Als dé belangenbehartiger voor de biotechnologiesector streven wij naar een omgeving waarin biotechnologiebedrijven een waardevolle bijdrage kunnen leveren aan een gezonde en duurzame samenleving. Een sterke basis voor intellectueel eigendom is daarvoor essentieel.
De Europese commissie deelt deze opvatting en is zich aan het oriënteren hoe intellectueel eigendom beter en breder ingezet en beschermd kan worden. Vandaar dit actieplan, waarvoor de Europese Commissie de mogelijkheid aan veldpartijen biedt om hun visie op het actieplan te geven.
HollandBIO maakt zich sterk voor adequate bescherming van intellectueel eigendom, omdat bedrijven zo in staat zijn om van een idee naar een concreet product te bewegen. Op deze manier faciliteert intellectueel eigendom een snelle en kostenefficiënte doorontwikkeling van academische kennis naar vernieuwende producten en technologieën.
Wij pleiten in onze inbreng daarom voor een systeem voor intellectueel eigendom:
Waar MKB-bedrijven eenvoudiger toegang toe hebben
Dat uniform is
Waarin het delen van data op vrijwillige basis gebeurt
https://www.hollandbio.nl/wp-content/uploads/2023/08/HollandBIO_logo.svg00HollandBIOhttps://www.hollandbio.nl/wp-content/uploads/2023/08/HollandBIO_logo.svgHollandBIO2020-08-13 13:41:172020-08-13 13:41:17Eenvoudig en uniform systeem voor intellectueel eigendom vergroot de maatschappelijke impact van kennis← #nieuws
BISC Global is pleased to announce the opening of a new branch in Basel, Switzerland. The new Basel location complements the global presence with its current offices in Belgium, and USA (Boston and San Francisco).
“We are thrilled to be expanding our footprint into the vibrant research community of Basel” said Maarten Braspenning, CEO of BISC Global. “As a bioinformatics, statistics and machine learning consulting company with a global view and local approach, we believe Switzerland is a key location for the next step in our company’s growth. We look forward to supporting the local pharma and biotech companies, as well as the research institutes and universities that call Switzerland home.”
As the go-to bioinformatics consulting company, BISC Global will offer high quality services for data-analysis, visualization, interpretation and storage. Dr. Remco Foppen will be leading the effort to help the Swiss research community to make the most of their data.
“I am excited to support the Swiss research community with varied bioinformatic tools, and Swiss bioinformaticians with a career at BISC Global” said Remco Foppen, Business Manager Switzerland at BISC Global.
Founded in 2017, BISC Global has grown to be a Top 10 Bioinformatics Consulting and Services Firm supporting world’s leading pharmaceutical and biotech companies. Through our offices in Ghent, Belgium; Basel, Switzerland; Boston, MA; and San Francisco, CA; BISC Global provides data-analytics, custom tool/pipeline development, and cloud solutions delivered on-site or remotely. By leveraging our global workforce of expert consultants, we support analysis across multiple domains, including machine learning (data mining, pattern recognition, image analysis, (un)supervised learning, neural networks, deep learning, etc.), bioinformatics (single-cell transcriptomics, metabolomics, metagenomics, epigenomics, etc.), and statistics (experimental design, mathematic modelling, signal-to-noise enhancement, and independent data cross validation).
https://www.hollandbio.nl/wp-content/uploads/2023/08/HollandBIO_logo.svg00HollandBIOhttps://www.hollandbio.nl/wp-content/uploads/2023/08/HollandBIO_logo.svgHollandBIO2020-08-13 10:43:272020-08-13 10:43:28BISC Global opens in Switzerland← #nieuws
Afgelopen week beschreef het Financieel Dagblad in een profielvan Seo Jung-Jin hoe deze oprichter Celltrion in een bochtige weg naar succesvol heeft geleid. Na zijn ontslag bij Daewoo, tijdens de Aziatische financiële crisis van eind jaren 90, richt hij met oud-collega’s het bedrijf Nexol op. Aanvankelijk is nog onduidelijk waar het bedrijf zich op zal richten, al ziet hij wel in dat het een industrie moest zijn die zich sterk zou gaan ontwikkelen. De als ingenieur geschoolde Jung-Jin richt zich met zijn bedrijf daarom op biotechnologie – en specifiek op biosimilars.
Het goed over het voetlicht brengen van de waarde van je bedrijf blijkt net zoals voor veel andere ondernemers binnen de biotechnologie ook in het verhaal van Jung-Jin van groot belang. Al langere tijd wijst HollandBIO op een aantal mogelijke verbeteringen in het financieringslandschap voor start- en scale-ups in de biotechnologiehoek, al is de nood in Europa echter nog niet zo hoog dat ondernemers hun organen als onderpand voor een lening hoeven aan te bieden. Jung-Jin kon, na tegenvallende resultaten van een geneesmiddel tegen HIV in 2004, niet meer terecht bij reguliere financierders en is uitgeweken naar woekeraars waar hij naar eigen zeggen zijn eigen organen als onderpand voor de lening heeft moeten geven. Dit alles is niet zonder resultaat geweest en inmiddels heeft het bedrijf dus zes geneesmiddelen op de markt. De afgelopen maanden gaat het erg goed met het bedrijf en is Jung-Jin zelfs de op een na rijkste Zuid-Koreaan, omdat het investeert in een behandeling tegen het coronavirus. Wie weet waar deze bochtige weg – niet bepaald zonder risico’s – eindigt… Benieuwd naar het hele verhaal? FD-abonnees lezen het hier.
https://www.hollandbio.nl/wp-content/uploads/2023/08/HollandBIO_logo.svg00HollandBIOhttps://www.hollandbio.nl/wp-content/uploads/2023/08/HollandBIO_logo.svgHollandBIO2020-08-11 16:23:112020-08-11 16:23:12De bochtige weg van Celltrion-oprichter Seo Jung-Jin← #nieuws
AON-platform with focus on therapies nearing phase I trials for forms of Spinocerebellar Ataxia and Huntington Disease
Other early discovery stage RNA editing platform focuses on RETT syndrome
Funding led by LSP, co-led by Kurma Partners, supported by Pontifax, Droia Genetic Disease, Polaris Partners and Pureos Bioventures
Vico Therapeutics,a Leiden, the Netherlands, based biotech company focusing on the development of RNA modulating therapies for rare neurological disorders, today announced that it has raised $31 million (€27 million) in a Series A financing round. Vico will use this funding to further advance its late preclinical stage Antisense OligoNucleotides (AON) lead platform for the development of therapies for different forms of Spinocerebellar Ataxia (SCA) and Huntington Disease (HD) into first-in-human clinical trials in late 2021. Its early discovery RNA editing platform is directed towards RETT syndrome. The financing was led by Life Science Partners (LSP), co-led by Kurma Partners, and supported by Pontifax, Droia Genetic Disease, Polaris Partners and Pureos Bioventures and Idinvest Partners.
Vico’s lead asset is an investigational AON therapy targeting expanded (CAG) trinucleotide repeats that translate into abnormally long and toxic polyglutamine (polyQ) stretches in proteins that cause a series of neurodegenerative polyQ disorders like Spinocerebellar Ataxia type 1 (SCA1), type 3 (SCA3) and Huntington’s disease (HD).
It has been demonstrated to preferentially reduce the levels of mutant polyQ compared to wildtype proteins. This was confirmed in several established mouse models for SCA1, SCA3 and Huntington Disease, with a long-term and widespread distribution of the compound throughout the central nervous system. Based on these encouraging data combined with the broad applicability of the lead compound to multiple different brain disorders with high unmet medical need, Vico is advancing this program towards a first-in-human trial expected in late 2021.
Luc Dochez, Founder and Chairman of Vico Therapeutics, stated: “This Series A funding will allow us to advance our lead program into the clinic and continue to build our capabilities as a leader in the development of novel therapies for serious CNS disorders. We see tremendous potential to advance the field and apply the breadth of our antisense oligonucleotide (AON) expertise to address severe neurological disorders. We are looking forward to accelerating the development of our platform technologies around AON technology and RNA-modulation/editing to bring best-in-class therapies to patients. The Vico team built this company around a unique synergy between state-of-the-art molecular biology, AON chemistry laboratories and industry experience in successfully developing drugs based on AON technology.”
Martijn Kleijwegt, managing partner at LSP, lead investor and board member, added: “Vico is building a leading team and has a cutting-edge infrastructure to engineer best-in-class therapies for severe neurological conditions and accelerate their advancement into human clinical trials. A major strength of Vico’s approach is the broad applicability to different polyQ diseases and the selectivity for mutant proteins.”
Vico’s Board will consist of Martijn Keijwegt, Managing Partner of LSP, Felice Verduyn-van Weegen, Investment Manager LSP, Rémi Droller, Managing Partner Kurma Partners, Silvia Noiman, Pontifax, Luc Dochez, Managing Partner, Droia Genetic Disease, Amy Schulman, Managing Partner Polaris Partners and Anja Harmeier, Partner Pureos Bioventures and Josh Mandel-Brehm, co-founder.
https://www.hollandbio.nl/wp-content/uploads/2023/08/HollandBIO_logo.svg00HollandBIOhttps://www.hollandbio.nl/wp-content/uploads/2023/08/HollandBIO_logo.svgHollandBIO2020-07-29 09:30:052020-07-29 09:30:06Biotech Vico Therapeutics raises $31 million (€27 million) in Series A financing round to advance therapies for rare central nervous system diseases← #nieuws
Interessante zomerlectuur in het Financieele Dagblad van octrooiadvocaat Wouter Pors (Bird & Bird) over de inzet van dwanglicenties voor geneesmiddelen. En wie zich in het onderwerp wil verdiepen: eerder verscheen van de hand van Pors op IE-Forum.nl al een uitgebreide juridische analyse over dwanglicenties voor geneesmiddelen, waarin hij uiteenzet dat het instrument niet zo eenvoudig ingezet kan worden zoals soms wordt voorgesteld.
https://www.hollandbio.nl/wp-content/uploads/2023/08/HollandBIO_logo.svg00HollandBIOhttps://www.hollandbio.nl/wp-content/uploads/2023/08/HollandBIO_logo.svgHollandBIO2020-07-28 18:36:282020-07-28 18:36:29Inzet van dwanglicenties voor geneesmiddelen – wordt er een probleem opgelost?← #nieuws
Companies to collaborate on mRNA vaccine and monoclonal antibody research programmes in infectious diseases
GSK to make equity investment of £130m (€150m) in CureVac, and an upfront payment of £104m (€120m)
GlaxoSmithKline plc (LSE/NYSE: GSK) and CureVac announced the signing of a strategic collaboration agreement for the research, development, manufacturing and commercialisation of up to five mRNA-based vaccines and monoclonal antibodies (mAbs) targeting infectious disease pathogens. The collaboration complements GSK’s existing mRNA capabilities with CureVac’s integrated mRNA platform.
mRNA (messenger RNA) technology is a rapidly progressing, cutting-edge platform for the development of new vaccines and medicines, potentially expanding the range of diseases which can be prevented or treated, while also promising to significantly speed up development and manufacturing. mRNA enables protein synthesis in the human body, carrying the genetic code required for cells to manufacture and express proteins. By using mRNA technology in vaccines and medicines, specific proteins, or antigens, can be produced by the body’s own cells, enabling the human immune system to prevent or fight disease.
CureVac’s leadership in mRNA technology, along with its mRNA manufacturing capability, complements GSK’s existing scientific leadership in vaccines, including GSK’s own self-amplifying mRNA (SAM) vaccine technology platform, and further builds on GSK’s growing capability in mAbs innovation, aligned to its R&D focus on the science of immunology. Advancing mRNA-based vaccine and treatment technologies is also expected to play a role in further improving response against future pandemics.
Roger Connor, President GSK Vaccines, said: “GSK’s self-amplifying mRNA (SAM) vaccine technology has shown us the potential of mRNA technology to advance the science of vaccine development, and CureVac’s experience complements our own expertise. Through the application of mRNA technology, including SAM, we hope to be able to develop and scale up advanced vaccines and therapies to treat and prevent infectious diseases quicker than ever before.”
Dr. Franz-Werner Haas, acting Chief Executive Officer of CureVac, added: “We are delighted to partner with GSK. With this collaboration, we are gaining a world-class partner whose expertise and global footprint will allow us to further develop and translate the value of our platform into potential products for the world.”
The companies will combine their mRNA expertise on development opportunities across a range of infectious disease pathogens, selected with the potential to best leverage the advantages of this platform technology, while addressing significant unmet medical need and economic burden. CureVac’s existing COVID-19 mRNA and rabies vaccines research programmes are not included in the collaboration announced today.
Under the terms of the deal, GSK will make an equity investment in CureVac of £130m (€150m), representing close to a 10% stake, an upfront cash payment of £104m (€120m) and a one-time reimbursable payment of £26m (€30m) for manufacturing capacity reservation, upon certification of CureVac’s commercial scale manufacturing facility currently under construction in Germany.
CureVac will be eligible to receive development and regulatory milestone payments of up to £277m (€320m), commercial milestone payments of up to £329m (€380m) and tiered royalties on product sales.
GSK will fund R&D activities at CureVac related to the development projects covered by the collaboration. CureVac will be responsible for the preclinical- and clinical-development through Phase 1 trials of these projects, after which GSK will be responsible for further development and commercialisation. CureVac will be responsible for the GMP manufacturing of the product candidates, including for commercialisation, and will retain commercialisation rights for selected countries for all product candidates.
Dutch scale-up PlantLab has raised a first external investment of 20 million from De Hoge Dennen Capital. The company has developed a globally patented technology for ‘vertical farming’, a hyper-efficient method for growing vegetables and fruits. It will use the injection of capital to open indoor production sites in various countries, including the Netherlands, US, and Bahamas.
Over the last 10 years, PlantLab has succeeded in developing an innovative and revolutionary technology for hyper-efficient urban farming, which is already being successfully applied in a commercial production site in Amsterdam. The new technology makes it possible to grow fresh, healthy, and delicious vegetables on a large scale very close to the consumer without using any chemical crop protection agents. On a surface area the size of only two football fields, it is now possible to produce enough crops to feed a city of 100,000 residents with 200 g of vegetables each on a daily basis.
’This injection of capital will enable us to open up additional production sites and further perfect our technology’, explains Michiel Peters, CEO of PlantLab. ‘The increasing population of the planet and the climate crisis are posing new and enormous challenges to the production of food for the world’s population. We have no choice but to grow our food more sustainably and efficiently, and that demands innovative and revolutionary solutions.’
PlantLab’s production sites can be set up anywhere in the world, even on barren land or urban areas. Thanks to optimised temperature, moisture, and light control, the crops grow to their full potential, while water use is reduced by as much as 95%. Light is provided by specially developed LEDs that provide the specific wavelength needed by the plant for photosynthesis. ‘Our technology makes it possible to grow crops anywhere in the world very close to the consumer. The crops then no longer need to be transported over long distances. The result: less CO2 emissions, lower cost, and less food waste’, says Peters.
De Hoge Dennen is part of the investment company founded by the De Rijcke family, the former owners of Kruidvat. The company has made previous investments in the online supermarket Picnic, the salad producer De Menken Keuken, and the electric bicycle brand QWIC. CFO Jelle Roodbeen: ‘We are convinced that PlantLab’s technology will make a real difference on a global level. It will make healthy and delicious vegetables affordable and accessible to everyone, in an environmentally friendly and sustainable fashion’.
In addition to the injection of capital by De Hoge Dennen, CFO Frank Roerink and CEO Michiel Peters are joining the scale-up company to strengthen the management team, which also includes the founding partners Leon van Duijn, Marcel Kers and John van Gemert. PlantLab has its vertical farming R&D centre, the biggest of its kind anywhere in the world, in Den Bosch, and a commercial production site in Amsterdam. PlantLab already employs over 60 people.
https://www.hollandbio.nl/wp-content/uploads/2023/08/HollandBIO_logo.svg00HollandBIOhttps://www.hollandbio.nl/wp-content/uploads/2023/08/HollandBIO_logo.svgHollandBIO2020-07-28 16:27:582020-07-28 16:27:59PlantLab raises €20 million in first external investment round← #nieuws
HollandBIO roept al jaren dat het vestigingsklimaat in Nederland fabelachtig is. De plannen om een research & development-campus voor onderzoek naar MS op te richten op het voormalige Land van Ooit in Drunen sluiten hier dan ook goed bij aan.
Jan Kelders, uitvinder van onder meer de prittstift, is de drijvende kracht achter de plannen om een onderzoekscampus naar neurologische aandoeningen op te zetten. Het onderzoek zal zich allereerst op MS en Alzheimer richten en wordt in de eerste plaats door hemzelf gefinancierd. Op de campus moet ook een diagnostisch centrum en zorgappartementen verrijzen.
De plannen laten zien dat Nederland een hotspot is voor biomedisch onderzoek, wat naadloos past bij andere succesverhalen in Zuid-Nederland zoals het Pivot Park in Oss en de Maastricht health campus. Om het sprookjeshuwelijk tussen biotech en Nederland nog lang niet te laten eindigen maken wij ons hard voor een IJzersterk innovatieklimaat. Daar lees je hier meer over.
iOnctura SA, a clinical stage biopharmaceutical company, developing a pipeline of next generation molecules targeting cancer and fibrosis announced that it has raised an additional EUR 5.1 million bringing the total Series A financing to EUR 20.1 million. New investor 3B Future Health Fund, previously known as Helsinn Investment Fund S.A., SICAR joins the existing blue chip investor syndicate of M Ventures, INKEF Capital, VI Partners, and Schroder Adveq, which all participated in the extension.
The funding will enable iOnctura to accelerate development of its next generation dual immune and tumour targeting therapies. Data emerging from early clinical evaluation of its lead molecule IOA-244, a highly selective PI3Kδ-inhibitor, in solid tumours is expected to enable progress into a Phase Ib trial earlier than anticipated and preclinical development of its second program, IOA-289, an ATX-inhibitor with dual utility in organ specific and cancer associated fibrosis will be expedited into human testing in early 2021. iOnctura has recently strengthened its team with the appointment of Dr. Joanna Horobin as Chair. Joanna is an accomplished drug developer and biotech leader with over 35 years of experience in the pharmaceutical and biotech sector in Europe and the US.
Catherine Pickering, Chief Executive Officer of iOnctura, said: “I am pleased to welcome 3B Future Health Fund to our strong investor syndicate. This oversubscribed Series A round provides further validation and support of our strategy as we progress our novel, highly selective, PI3Kδ inhibitor and our differentiated ATX inhibitor through clinical development.”
Riccardo Braglia, 3B Future Health Fund Chairman and Helsinn Group Vice Chairman and Chief Executive Officer, commented: “We look to invest in early-stage companies which are developing novel treatments in areas of high unmet patient need. We have been very impressed with the world class team at iOnctura and the potential of its next generation molecules targeting cancer and fibrosis.”
https://www.hollandbio.nl/wp-content/uploads/2023/08/HollandBIO_logo.svg00HollandBIOhttps://www.hollandbio.nl/wp-content/uploads/2023/08/HollandBIO_logo.svgHollandBIO2020-07-21 21:15:282020-07-21 21:25:33iOnctura Extends Series A to EUR 20.1M